A	O
neutralizing	B:C0475463
anti-G-CSFR	I:C0475463
antibody	I:C0475463
blocks	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
induced	O
neutrophilia	O
without	O
inducing	O
neutropenia	O
in	O
nonhuman	O
primates	I:C0237798
Neutrophils	O
are	O
the	O
most	O
abundant	O
WBCs	O
and	O
have	O
an	O
essential	O
role	O
in	O
the	O
clearance	O
of	O
pathogens	O
.	O

A	O
neutralizing	O
anti-G-CSFR	I:C0475463
antibody	I:C0475463
blocks	O
G	B:C0079459
-	I:C0079459
CSF	I:C0079459
-	O
induced	O
neutrophilia	O
without	O
inducing	O
neutropenia	O
in	O
nonhuman	O
primates	I:C0237798
Neutrophils	O
are	O
the	O
most	O
abundant	O
WBCs	O
and	O
have	O
an	O
essential	O
role	O
in	O
the	O
clearance	O
of	O
pathogens	O
.	O

A	O
neutralizing	O
anti-G-CSFR	I:C0475463
antibody	I:C0475463
blocks	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
induced	O
neutrophilia	B:C3665444
without	O
inducing	O
neutropenia	O
in	O
nonhuman	O
primates	I:C0237798
Neutrophils	O
are	O
the	O
most	O
abundant	O
WBCs	O
and	O
have	O
an	O
essential	O
role	O
in	O
the	O
clearance	O
of	O
pathogens	O
.	O

A	O
neutralizing	O
anti-G-CSFR	I:C0475463
antibody	I:C0475463
blocks	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
induced	O
neutrophilia	O
without	O
inducing	O
neutropenia	B:C0027947
in	O
nonhuman	O
primates	I:C0237798
Neutrophils	O
are	O
the	O
most	O
abundant	O
WBCs	O
and	O
have	O
an	O
essential	O
role	O
in	O
the	O
clearance	O
of	O
pathogens	O
.	O

A	O
neutralizing	O
anti-G-CSFR	I:C0475463
antibody	I:C0475463
blocks	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
induced	O
neutrophilia	O
without	O
inducing	O
neutropenia	O
in	O
nonhuman	B:C0237798
primates	I:C0237798
Neutrophils	O
are	O
the	O
most	O
abundant	O
WBCs	O
and	O
have	O
an	O
essential	O
role	O
in	O
the	O
clearance	O
of	O
pathogens	O
.	O

A	O
neutralizing	O
anti-G-CSFR	I:C0475463
antibody	I:C0475463
blocks	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
induced	O
neutrophilia	O
without	O
inducing	O
neutropenia	O
in	O
nonhuman	O
primates	I:C0237798
Neutrophils	B:C0027950
are	O
the	O
most	O
abundant	O
WBCs	O
and	O
have	O
an	O
essential	O
role	O
in	O
the	O
clearance	O
of	O
pathogens	O
.	O

A	O
neutralizing	O
anti-G-CSFR	I:C0475463
antibody	I:C0475463
blocks	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
induced	O
neutrophilia	O
without	O
inducing	O
neutropenia	O
in	O
nonhuman	O
primates	I:C0237798
Neutrophils	O
are	O
the	O
most	O
abundant	O
WBCs	B:C0023516
and	O
have	O
an	O
essential	O
role	O
in	O
the	O
clearance	O
of	O
pathogens	O
.	O

Tight	O
regulation	B:C1327622
of	O
neutrophil	O
numbers	O
and	O
their	O
recruitment	O
to	O
sites	O
of	O
inflammation	O
is	O
critical	O
in	O
maintaining	O
a	O
balanced	O
immune	O
response	I:C0301872
.	O

Tight	O
regulation	O
of	O
neutrophil	B:C0027950
numbers	O
and	O
their	O
recruitment	O
to	O
sites	O
of	O
inflammation	O
is	O
critical	O
in	O
maintaining	O
a	O
balanced	O
immune	O
response	I:C0301872
.	O

Tight	O
regulation	O
of	O
neutrophil	O
numbers	O
and	O
their	O
recruitment	O
to	O
sites	O
of	O
inflammation	B:C0021368
is	O
critical	O
in	O
maintaining	O
a	O
balanced	O
immune	O
response	I:C0301872
.	O

Tight	O
regulation	O
of	O
neutrophil	O
numbers	O
and	O
their	O
recruitment	O
to	O
sites	O
of	O
inflammation	O
is	O
critical	O
in	O
maintaining	O
a	O
balanced	O
immune	B:C0301872
response	I:C0301872
.	O

In	O
various	O
inflammatory	O
conditions	O
,	O
such	O
as	O
rheumatoid	B:C0003873
arthritis	I:C0003873
,	O
vasculitis	O
,	O
cystic	O
fibrosis	I:C0010674
,	O
and	O
inflammatory	O
bowel	I:C0021390
disease	I:C0021390
,	O
increased	O
serum	O
G	O
-	I:C0079459
CSF	I:C0079459
correlates	O
with	O
neutrophilia	O
and	O
enhanced	O
neutrophil	O
infiltration	I:C0751982
into	O
inflamed	O
tissues	O
.	O

In	O
various	O
inflammatory	O
conditions	O
,	O
such	O
as	O
rheumatoid	O
arthritis	I:C0003873
,	O
vasculitis	B:C0042384
,	O
cystic	O
fibrosis	I:C0010674
,	O
and	O
inflammatory	O
bowel	I:C0021390
disease	I:C0021390
,	O
increased	O
serum	O
G	O
-	I:C0079459
CSF	I:C0079459
correlates	O
with	O
neutrophilia	O
and	O
enhanced	O
neutrophil	O
infiltration	I:C0751982
into	O
inflamed	O
tissues	O
.	O

In	O
various	O
inflammatory	O
conditions	O
,	O
such	O
as	O
rheumatoid	O
arthritis	I:C0003873
,	O
vasculitis	O
,	O
cystic	B:C0010674
fibrosis	I:C0010674
,	O
and	O
inflammatory	O
bowel	I:C0021390
disease	I:C0021390
,	O
increased	O
serum	O
G	O
-	I:C0079459
CSF	I:C0079459
correlates	O
with	O
neutrophilia	O
and	O
enhanced	O
neutrophil	O
infiltration	I:C0751982
into	O
inflamed	O
tissues	O
.	O

In	O
various	O
inflammatory	O
conditions	O
,	O
such	O
as	O
rheumatoid	O
arthritis	I:C0003873
,	O
vasculitis	O
,	O
cystic	O
fibrosis	I:C0010674
,	O
and	O
inflammatory	B:C0021390
bowel	I:C0021390
disease	I:C0021390
,	O
increased	O
serum	O
G	O
-	I:C0079459
CSF	I:C0079459
correlates	O
with	O
neutrophilia	O
and	O
enhanced	O
neutrophil	O
infiltration	I:C0751982
into	O
inflamed	O
tissues	O
.	O

In	O
various	O
inflammatory	O
conditions	O
,	O
such	O
as	O
rheumatoid	O
arthritis	I:C0003873
,	O
vasculitis	O
,	O
cystic	O
fibrosis	I:C0010674
,	O
and	O
inflammatory	O
bowel	I:C0021390
disease	I:C0021390
,	O
increased	O
serum	B:C0229671
G	O
-	I:C0079459
CSF	I:C0079459
correlates	O
with	O
neutrophilia	O
and	O
enhanced	O
neutrophil	O
infiltration	I:C0751982
into	O
inflamed	O
tissues	O
.	O

In	O
various	O
inflammatory	O
conditions	O
,	O
such	O
as	O
rheumatoid	O
arthritis	I:C0003873
,	O
vasculitis	O
,	O
cystic	O
fibrosis	I:C0010674
,	O
and	O
inflammatory	O
bowel	I:C0021390
disease	I:C0021390
,	O
increased	O
serum	O
G	B:C0079459
-	I:C0079459
CSF	I:C0079459
correlates	O
with	O
neutrophilia	O
and	O
enhanced	O
neutrophil	O
infiltration	I:C0751982
into	O
inflamed	O
tissues	O
.	O

In	O
various	O
inflammatory	O
conditions	O
,	O
such	O
as	O
rheumatoid	O
arthritis	I:C0003873
,	O
vasculitis	O
,	O
cystic	O
fibrosis	I:C0010674
,	O
and	O
inflammatory	O
bowel	I:C0021390
disease	I:C0021390
,	O
increased	O
serum	O
G	O
-	I:C0079459
CSF	I:C0079459
correlates	O
with	O
neutrophilia	B:C3665444
and	O
enhanced	O
neutrophil	O
infiltration	I:C0751982
into	O
inflamed	O
tissues	O
.	O

In	O
various	O
inflammatory	O
conditions	O
,	O
such	O
as	O
rheumatoid	O
arthritis	I:C0003873
,	O
vasculitis	O
,	O
cystic	O
fibrosis	I:C0010674
,	O
and	O
inflammatory	O
bowel	I:C0021390
disease	I:C0021390
,	O
increased	O
serum	O
G	O
-	I:C0079459
CSF	I:C0079459
correlates	O
with	O
neutrophilia	O
and	O
enhanced	O
neutrophil	B:C0751982
infiltration	I:C0751982
into	O
inflamed	O
tissues	O
.	O

In	O
various	O
inflammatory	O
conditions	O
,	O
such	O
as	O
rheumatoid	O
arthritis	I:C0003873
,	O
vasculitis	O
,	O
cystic	O
fibrosis	I:C0010674
,	O
and	O
inflammatory	O
bowel	I:C0021390
disease	I:C0021390
,	O
increased	O
serum	O
G	O
-	I:C0079459
CSF	I:C0079459
correlates	O
with	O
neutrophilia	O
and	O
enhanced	O
neutrophil	O
infiltration	I:C0751982
into	O
inflamed	O
tissues	B:C0040300
.	O

We	O
describe	O
a	O
fully	O
human	B:C0086418
therapeutic	O
anti-G-CSFR	O
antibody	I:C0475463
(	O
CSL324	O
)	O
that	O
is	O
safe	O
and	O
well	O
tolerated	O
when	O
administered	O
via	O
i.v.	O
infusion	O
to	O
cynomolgus	O
macaques	I:C0024399
.	O

We	O
describe	O
a	O
fully	O
human	O
therapeutic	O
anti-G-CSFR	B:C0475463
antibody	I:C0475463
(	O
CSL324	O
)	O
that	O
is	O
safe	O
and	O
well	O
tolerated	O
when	O
administered	O
via	O
i.v.	O
infusion	O
to	O
cynomolgus	O
macaques	I:C0024399
.	O

We	O
describe	O
a	O
fully	O
human	O
therapeutic	O
anti-G-CSFR	O
antibody	I:C0475463
(	O
CSL324	B:C0475463
)	O
that	O
is	O
safe	O
and	O
well	O
tolerated	O
when	O
administered	O
via	O
i.v.	O
infusion	O
to	O
cynomolgus	O
macaques	I:C0024399
.	O

We	O
describe	O
a	O
fully	O
human	O
therapeutic	O
anti-G-CSFR	O
antibody	I:C0475463
(	O
CSL324	O
)	O
that	O
is	O
safe	O
and	O
well	O
tolerated	O
when	O
administered	O
via	O
i.v.	O
infusion	B:C0574032
to	O
cynomolgus	O
macaques	I:C0024399
.	O

We	O
describe	O
a	O
fully	O
human	O
therapeutic	O
anti-G-CSFR	O
antibody	I:C0475463
(	O
CSL324	O
)	O
that	O
is	O
safe	O
and	O
well	O
tolerated	O
when	O
administered	O
via	O
i.v.	O
infusion	O
to	O
cynomolgus	B:C0024399
macaques	I:C0024399
.	O

CSL324	B:C0475463
was	O
effective	O
in	O
controlling	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
mediated	O
neutrophilia	O
when	O
administered	O
either	O
before	O
or	O
after	O
G	O
-	I:C0079459
CSF	I:C0079459
.	O

CSL324	O
was	O
effective	O
in	O
controlling	O
G	B:C0079459
-	I:C0079459
CSF	I:C0079459
-	O
mediated	O
neutrophilia	O
when	O
administered	O
either	O
before	O
or	O
after	O
G	O
-	I:C0079459
CSF	I:C0079459
.	O

CSL324	O
was	O
effective	O
in	O
controlling	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
mediated	O
neutrophilia	B:C3665444
when	O
administered	O
either	O
before	O
or	O
after	O
G	O
-	I:C0079459
CSF	I:C0079459
.	O

CSL324	O
was	O
effective	O
in	O
controlling	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
mediated	O
neutrophilia	O
when	O
administered	O
either	O
before	O
or	O
after	O
G	B:C0079459
-	I:C0079459
CSF	I:C0079459
.	O

A	O
single	O
ascending	O
-	O
dose	O
study	O
showed	O
CSL324	B:C0475463
did	O
not	O
alter	O
steady	O
-	O
state	O
neutrophil	O
numbers	I:C0200633
,	O
even	O
at	O
doses	O
sufficient	O
to	O
completely	O
prevent	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
mediated	O
neutrophilia	O
.	O

A	O
single	O
ascending	O
-	O
dose	O
study	O
showed	O
CSL324	O
did	O
not	O
alter	O
steady	O
-	O
state	O
neutrophil	B:C0200633
numbers	I:C0200633
,	O
even	O
at	O
doses	O
sufficient	O
to	O
completely	O
prevent	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
mediated	O
neutrophilia	O
.	O

A	O
single	O
ascending	O
-	O
dose	O
study	O
showed	O
CSL324	O
did	O
not	O
alter	O
steady	O
-	O
state	O
neutrophil	O
numbers	I:C0200633
,	O
even	O
at	O
doses	O
sufficient	O
to	O
completely	O
prevent	O
G	B:C0079459
-	I:C0079459
CSF	I:C0079459
-	O
mediated	O
neutrophilia	O
.	O

A	O
single	O
ascending	O
-	O
dose	O
study	O
showed	O
CSL324	O
did	O
not	O
alter	O
steady	O
-	O
state	O
neutrophil	O
numbers	I:C0200633
,	O
even	O
at	O
doses	O
sufficient	O
to	O
completely	O
prevent	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
mediated	O
neutrophilia	B:C3665444
.	O

Weekly	O
infusions	B:C0574032
of	O
CSL324	O
(	O
≤10	O
mg/kg	O
)	O
for	O
3	O
wk	O
completely	O
neutralized	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
mediated	O
pSTAT3	O
phosphorylation	O
without	O
neutropenia	O
.	O

Weekly	O
infusions	O
of	O
CSL324	B:C0475463
(	O
≤10	O
mg/kg	O
)	O
for	O
3	O
wk	O
completely	O
neutralized	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
mediated	O
pSTAT3	O
phosphorylation	O
without	O
neutropenia	O
.	O

Weekly	O
infusions	O
of	O
CSL324	O
(	O
≤10	O
mg/kg	O
)	O
for	O
3	O
wk	O
completely	O
neutralized	O
G	B:C0079459
-	I:C0079459
CSF	I:C0079459
-	O
mediated	O
pSTAT3	O
phosphorylation	O
without	O
neutropenia	O
.	O

Weekly	O
infusions	O
of	O
CSL324	O
(	O
≤10	O
mg/kg	O
)	O
for	O
3	O
wk	O
completely	O
neutralized	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
mediated	O
pSTAT3	B:C0253050
phosphorylation	O
without	O
neutropenia	O
.	O

Weekly	O
infusions	O
of	O
CSL324	O
(	O
≤10	O
mg/kg	O
)	O
for	O
3	O
wk	O
completely	O
neutralized	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
mediated	O
pSTAT3	O
phosphorylation	B:C0031715
without	O
neutropenia	O
.	O

Weekly	O
infusions	O
of	O
CSL324	O
(	O
≤10	O
mg/kg	O
)	O
for	O
3	O
wk	O
completely	O
neutralized	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
mediated	O
pSTAT3	O
phosphorylation	O
without	O
neutropenia	B:C0027947
.	O

Moreover	O
,	O
repeat	O
dosing	O
up	O
to	O
100	O
mg	O
/	O
kg	O
for	O
12	O
wk	O
did	O
not	O
result	O
in	O
neutropenia	B:C0027947
at	O
any	O
point	O
,	O
including	O
the	O
12	O
-	O
wk	O
follow	O
-	I:C1522577
up	I:C1522577
after	O
the	O
last	O
infusion	O
.	O

Moreover	O
,	O
repeat	O
dosing	O
up	O
to	O
100	O
mg	O
/	O
kg	O
for	O
12	O
wk	O
did	O
not	O
result	O
in	O
neutropenia	O
at	O
any	O
point	O
,	O
including	O
the	O
12	O
-	O
wk	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
after	O
the	O
last	O
infusion	O
.	O

Moreover	O
,	O
repeat	O
dosing	O
up	O
to	O
100	O
mg	O
/	O
kg	O
for	O
12	O
wk	O
did	O
not	O
result	O
in	O
neutropenia	O
at	O
any	O
point	O
,	O
including	O
the	O
12	O
-	O
wk	O
follow	O
-	I:C1522577
up	I:C1522577
after	O
the	O
last	O
infusion	B:C0574032
.	O

In	O
addition	O
,	O
CSL324	B:C0475463
had	O
no	O
observable	O
effect	O
on	O
basic	O
neutrophil	O
functions	O
,	O
such	O
as	O
phagocytosis	O
and	O
oxidative	O
burst	I:C0085416
.	O

In	O
addition	O
,	O
CSL324	O
had	O
no	O
observable	O
effect	O
on	O
basic	O
neutrophil	B:C0027950
functions	O
,	O
such	O
as	O
phagocytosis	O
and	O
oxidative	O
burst	I:C0085416
.	O

In	O
addition	O
,	O
CSL324	O
had	O
no	O
observable	O
effect	O
on	O
basic	O
neutrophil	O
functions	O
,	O
such	O
as	O
phagocytosis	B:C0031308
and	O
oxidative	O
burst	I:C0085416
.	O

In	O
addition	O
,	O
CSL324	O
had	O
no	O
observable	O
effect	O
on	O
basic	O
neutrophil	O
functions	O
,	O
such	O
as	O
phagocytosis	O
and	O
oxidative	B:C0085416
burst	I:C0085416
.	O

These	O
data	O
suggest	O
that	O
targeting	O
G	B:C0080090
-	I:C0080090
CSFR	I:C0080090
may	O
provide	O
a	O
safe	O
and	O
effective	O
means	O
of	O
controlling	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
mediated	O
neutrophilia	O
as	O
observed	O
in	O
various	O
inflammatory	O
diseases	I:C1290884
.	O

These	O
data	O
suggest	O
that	O
targeting	O
G	O
-	I:C0080090
CSFR	I:C0080090
may	O
provide	O
a	O
safe	O
and	O
effective	O
means	O
of	O
controlling	O
G	B:C0079459
-	I:C0079459
CSF	I:C0079459
-	O
mediated	O
neutrophilia	O
as	O
observed	O
in	O
various	O
inflammatory	O
diseases	I:C1290884
.	O

These	O
data	O
suggest	O
that	O
targeting	O
G	O
-	I:C0080090
CSFR	I:C0080090
may	O
provide	O
a	O
safe	O
and	O
effective	O
means	O
of	O
controlling	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
mediated	O
neutrophilia	B:C3665444
as	O
observed	O
in	O
various	O
inflammatory	O
diseases	I:C1290884
.	O

These	O
data	O
suggest	O
that	O
targeting	O
G	O
-	I:C0080090
CSFR	I:C0080090
may	O
provide	O
a	O
safe	O
and	O
effective	O
means	O
of	O
controlling	O
G	O
-	I:C0079459
CSF	I:C0079459
-	O
mediated	O
neutrophilia	O
as	O
observed	O
in	O
various	O
inflammatory	B:C1290884
diseases	I:C1290884
.	O

